Skip to main content

Some NLM-NCBI services and products are experiencing heavy traffic, which may affect performance and availability. We apologize for the inconvenience and appreciate your patience. For assistance, please contact our Help Desk at info@ncbi.nlm.nih.gov.

International Journal of Molecular Sciences logoLink to International Journal of Molecular Sciences
. 2023 Jul 18;24(14):11613. doi: 10.3390/ijms241411613

Impact of Mir196a-2 Genotypes on Colorectal Cancer Risk in Taiwan

Te-Cheng Yueh 1,2,3, Yun-Chi Wang 3,4, Yu-Ting Chin 3,4, Yi-Chih Hung 3,4, Mei-Chin Mong 5, Ya-Chen Yang 5, Jen-Sheng Pei 6, Jian Gu 7, Chia-Wen Tsai 3,4,7, Da-Tian Bau 3,4,8,*, Wen-Shin Chang 3,4,7,*
Editor: Mohamed Raafat El-Gewely
PMCID: PMC10380589  PMID: 37511371

Abstract

We aimed to investigate the association between genotypes for mir146a and mir196a-2 and the risk of developing colorectal cancer (CRC). We used polymerase chain reaction-restriction fragment length polymorphism (PCR-RFLP) to determine the mir146a rs2910164 and mir196a-2 rs11614913 genotypes in 362 CRC patients and 362 controls. We also assessed the interactions between these genotypes and age, gender, smoking, alcohol consumption, and BMI status on CRC risk. Additionally, the serum expression level of mir196a-2 was quantified using quantitative reverse transcription-PCR. Our findings demonstrated that among the controls, the proportions of TT, CT, and CC genotypes of mir196a-2 rs11614913 were 32.3%, 48.1%, and 19.6%, respectively. As for the cases, the proportions were 24.6%, 45.0%, and 30.4%, respectively. Logistic regression analysis revealed that the CC genotype carriers had a 2.04-fold increased risk (95% confidence interval [CI] = 1.36–3.06, p = 0.0008). Furthermore, carriers of the CT + CC genotypes also exhibited a significant association with CRC risk (odds ratio [OR] = 1.46, 95% CI = 1.06–2.03, p = 0.0261). Moreover, carriers of the CC genotype had significantly higher serum levels of mir196a-2 compared to those with the TT genotype (p < 0.0001), indicating a genotype-phenotype correlation. No association was found regarding mir146a rs2910164. In conclusion, mir196a-2 rs2910164 genotypes, along with their associated expression, can serve as predictive markers for CRC risk.

Keywords: colorectal cancer, genotype, mir146a, mir196a-2, phenotype, polymorphism

1. Introduction

Colorectal cancer (CRC) is highly prevalent globally, ranking as the second most common cancer among women and the third most common among men [1,2,3]. The incidence and mortality rates of CRC vary significantly among countries, with differences of up to tenfold [2,3,4]. Several factors contribute to this variation, including meat consumption, cigarette smoking, and exposure to carcinogens, which account for approximately 85% of CRC cases [5,6].

In Taiwan, CRC is a significant health concern, with the highest incidence rate among all types of cancer and ranking third in terms of mortality, following lung cancer and hepatoma. The presence of a familial cancer history in approximately 15–20% of CRC cases [7,8], indicates the potential contribution of genetic factors to the development of CRC. In recent years, a plethora of genetic biomarkers associated with CRC have been identified [9,10,11,12,13,14], and there is still considerable interest in identifying additional genetic susceptibility factors and investigating the interactions between genetic factors and other risk factors. Gaining a better understanding of the genetic contributions to CRC can assist scientists in developing more targeted and precise approaches to cancer prevention and therapy.

MicroRNAs (miRNAs) are single-stranded, non-coding RNAs that function as negative regulators of the expression level of genes [15]. They play pivotal roles in diverse biological processes, encompassing embryonic development, cell proliferation, apoptosis, tissue remodeling, and notably, the process of carcinogenesis [16,17]. Genetic variations have been identified in both miRNA genes and their target genes, and these variations have been associated with a wide range of human diseases. Meanwhile, there is mounting evidence supporting the idea that dysregulated miRNAs play critical roles in tumorigenesis [18,19]. In CRC, several miRNAs have been identified to modulate cell proliferation, migration, apoptosis, and response to radiation in both CRC cells and patient samples. These miRNAs include miRNA 133A [20], miRNA 483-3p [21], miRNA 652 [22], and miRNA-627-5p [23]. Considering their dysregulation and significant correlation with numerous types of cancer, miRNAs emerge as promising targets for novel therapeutic strategies. Moreover, their secretion into extracellular fluids positions them as promising biomarkers for accessing tumor initiation, progression, metastasis, and tumor survival. However, the genetic contribution of miRNAs to the development of cancer has not yet been thoroughly investigated.

Single nucleotide polymorphisms (SNPs) are subtle genetic variations that commonly occur within miRNA genes. These genetic variations can potentially affect the expression and function of specific miRNAs, thereby contributing to tumorigenesis [24]. In the recent decade, accumulated studies have examined the relationship between numerous SNPs in miRNAs and the risk of CRC [25]. Among these SNPs, mir146a rs2910164 is the most extensively studied. The C allele of this SNP reduces the nuclear processing efficiency of pri-mir146a, resulting in a less stable structure and decreased mir146a expression [26]. In 2020, Santos and colleagues reported that mir146a expression within the tumor tissues was significantly higher among the CRC patients carrying the mir146a rs2910164 GG genotype compared to those carrying the GC or CC genotypes [27]. Regarding the association between this SNP and CRC risk, while the majority of the literature indicates no association [27,28,29,30,31,32,33,34], there are specific studies that have found associations within certain populations [35,36,37]. The CC genotype has been associated with increased CRC risks in populations from Greece [38], Korea [39], and China [35]. However, contrasting associations have been reported in Lithuania [40] and China [41,42]. Another frequently studied miRNA SNP is mir196a-2 rs11614913. Zhan and colleagues reported that this SNP influences RNA maturation and its interaction with other molecules [43]. Several studies have investigated its association with CRC risk, and the results have been inconsistent [28,29,30,31,33,37,38,40,42,43,44,45,46,47,48].

In this study, we aim to investigate the associations of the mir146a and mir196a-2 SNPs with the risk of CRC among a Taiwanese population. The physical locations of these two SNPs are illustrated in Figure 1. Additionally, we aim to assess the potential interactions between genotypes and factors such as age, gender, smoking, and alcohol consumption in relation to CRC risk. Furthermore, we explored the correlation between genotypes and miRNA expression. Importantly, we conducted a thorough review of the existing literature and presented a concise discussion of its findings.

Figure 1.

Figure 1

Physical maps of (A) mir146a rs2910164 (A) and (B) mir196a-2 rs11614913 SNPs investigated in this study.

2. Results

2.1. Characteristics of Study Population

Table 1 presents the demographic and clinical characteristics of the cases and controls. The controls were 1:1 matched to the cases based on age and gender. There were no significant differences in the frequency of smoking (p = 0.543), alcohol consumption (p = 0.441), or BMI (p = 0.181) between the cases and controls.

Table 1.

Selected characteristics of the 362 CRC patients and 362 non-cancer controls.

Characteristic Controls, n = 362 Cases, n = 362 p-Value a
n % n %
Age (years)
  ≤60 95 26.2% 95 26.2% 1.0000
  >60 267 73.8% 267 73.8%
Gender
  Male 203 56.1% 203 56.1% 1.0000
  Female 159 43.6% 159 43.9%
Smoking
  Yes 84 23.2% 91 25.1% 0.5434
  No 278 76.8% 271 74.9%
Alcohol drinking
  Yes 51 14.1% 44 12.2% 0.4410
  No 311 85.9% 318 87.8%
BMI
  <24 175 48.3% 193 53.3% 0.1809
  ≥24 187 51.7% 169 46.7%
Tumor size (cm)
  <5 195 53.9%
  ≥5 167 46.1%
Location
  Colon 257 71.0%
  Rectum 105 29.0%
Lymph node involvement
  Negative 210 58.0%
  Positive 152 42.0%
Stage
  Stage 1 94 26.0%
  Stage 2 72 19.9%
  Stage 3 134 37.0%
  Stage 4 62 17.1%

SD, Standard deviation; BMI, body mass index; a based on Chi-square test with Yates’ correction.

2.2. Mir196a-2 Genotypes, but Not Mir146a Genotypes, Were Associated with CRC Risk

The mir146a rs2910164 and mir196a-2 rs11614913 genotypic frequencies in the control groups fit well to the Hardy–Weinberg equation (p = 0.6631 and 0.1155, respectively). The distribution of genotypes does not show any significant differences among individuals with different characteristics (Supplemental Table S1). A significant association was observed between mir196a-2 rs11614913 genotypes and the risk of CRC. Compared to the TT genotype, the OR for the heterozygous variant genotype CT carriers was 1.23 (95% CI = 0.87–1.75), whereas the homozygous variant genotype CC carriers were under a 2.04-fold increased CRC risk (OR = 2.04, 95% CI = 1.36–3.06) (p for trend = 0.0019). Individuals carrying the variant genotypes (CT + CC) had a 1.46-fold increased risk of CRC (OR = 1.46, 95% CI = 1.06–2.03) (Table 2). In contrast, there was no significant association between mir146a rs2910164 and CRC risk (Table 3).

Table 2.

Associations between mir196a-2 rs11614913 genotypes and CRC risk in Taiwan.

SNP Genotype Cases Controls p-Value OR (95%CI)
rs11614913 TT 89 (24.6%) 117 (32.3%) 1.00 (Ref)
CT 163 (45.0%) 174 (48.1%) 0.2792 1.23 (0.87–1.75)
CC 110 (30.4%) 71 (19.6%) 0.0008 * 2.04 (1.36–3.06)
P trend 0.0019 *
CT + CC 273 (75.4%) 245 (67.7%) 0.0261 * 1.46 (1.06–2.03)
P HWE 0.6631

OR: Odds ratio; CI: confidence interval; p-Values were calculated by Chi-square with Yates’ correction; HWE: Hardy–Weinberg Equilibrium; Ptrend, p-Value for trend analysis; PHWE, p-Value for Hardy–Weinberg equilibrium analysis *: p < 0.05; the significant parts are marked in bold.

Table 3.

Associations between mir146a rs2910164 genotypes and CRC risk in Taiwan.

SNP Genotype Cases Controls p-Value OR (95%CI)
rs2910164 CC 124 (34.3%) 119 (32.9%) 1.00 (Ref)
CG 160 (44.2%) 164 (45.3%) 0.7618 0.94 (0.67–1.31)
GG 78 (21.5%) 79 (21.8%) 0.8723 0.95 (0.63–1.42)
P trend 0.9237
CG + GG 238 (65.7%) 243 (67.1%) 0.7529 0.94 (0.69–1.28)
P HWE 0.1155

OR: Odds ratio; CI: confidence interval; p-Values were calculated by Chi-square with Yates’ correction; HWE: Hardy–Weinberg Equilibrium; Ptrend, p-Value for trend analysis; PHWE, p-Value for Hardy–Weinberg equilibrium analysis.

2.3. Associations of Mir196a-2 and Mir146a Alleles with CRC Risk

Table 4 shows the allelic test of mir146a rs2910164 and mir196a-2 rs11614913 in relation to CRC risk. The percentage of the G allele at mir146a rs2910164 in the control group was 45.5%, slightly higher than that (43.6%) observed in the CRC patient group. However, for mir196a-2 rs11614913, the percentage of C allele was significantly higher in the CRC case (52.9%) than the control group (43.6%) (p = 0.0005). This corresponded to a 1.45-fold (95% CI = 1.18–1.78) increased risk of CRC for the C allele carriers compared to those of the T (OR = 1.45, 95% CI = 1.18–1.78) (Table 4).

Table 4.

Associations of mir146a rs2910164 and mir196a-2 rs11614913 alleles with CRC risk.

Allele Cases Controls p-Value OR (95%CI)
mir146a rs2910164
  C 408 (56.4%) 402 (55.5%) 1.00 (Ref)
  G 316 (43.6%) 322 (45.5%) 0.7913 0.97 (0.79–1.19)
mir196a-2 rs11614913
  T 341 (47.1%) 408 (56.4%) 1.00 (Ref)
  C 383 (52.9%) 316 (43.6%) 0.0005 * 1.45 (1.18–1.78)

p-Value was calculated by Chi-square with Yates’ correction; *: p < 0.05; the significant parts are marked in bold.

2.4. Stratified Analyses of Mir196a-2 Genotypes by Age, Gender, Smoking, Alcohol Drinking Behaviors and BMI Status

We then conducted stratified analyses investigating the associations between mir196a-2 rs11614913 with the risk of CRC based on differential age, gender, smoking, alcohol drinking behaviors, and BMI status (Table 5). Concisely, the associations between the mir196a-2 rs11614913 SNP and CRC risk were statistically significant in all the strata, except for the smokers and drinkers. In the smoker and drinker subgroups, the risk for the CC genotype (OR = 2.11 and 2.36, 95% CI = 0.92–4.84 and 0.76–7.34, p = 0.1169 and 0.2239, respectively) did not reach a significant level. These findings cannot be settled down as a conclusion due to the small sample size tested.

Table 5.

Associations between mir196a-2 rs11614913 genotypes and CRC risk in stratified analyses.

Characteristics Controls Cases OR (95% CI) a aOR (95% CI) b p-Value c
   Age
    ≤60 years old
       TT 32 23 1.00 (ref) 1.00 (ref)
       CT 48 43 1.25 (0.63–2.45) 1.21 (0.67–2.39) 0.6400
       CC 15 29 2.69 (1.18–6.12) 2.77 (1.23–4.98) 0.0291 *
    >60 years old
       TT 85 66 1.00 (ref) 1.00 (ref)
       CT 126 120 1.23 (0.82–1.84) 1.33 (0.79–2.11) 0.3791
       CC 56 81 1.86 (1.17–2.98) 2.04 (1.24–3.58) 0.0126 *
   Gender
    Males
       TT 69 52 1.00 (ref) 1.00 (ref)
       CT 94 89 1.26 (0.79–1.99) 1.19 (0.81–1.86) 0.3948
       CC 40 62 2.06 (1.20–3.52) 2.28 (1.19–3.23) 0.0119 *
    Females
       TT 48 37 1.00 (ref) 1.00 (ref)
       CT 80 74 1.20 (0.70–2.04) 1.19 (0.74–2.17) 0.5922
       CC 31 48 2.01 (1.08–3.74) 2.04 (1.12–3.88) 0.0404 *
   Smoking behaviors
    Non-smokers
       TT 91 68 1.00 (ref) 1.00 (ref)
       CT 133 122 1.23 (0.82–1.83) 1.31 (0.92–2.53) 0.3646
       CC 54 81 2.01 (1.26–3.20) 2.27 (1.23–2.97) 0.0047 *
    Smokers
       TT 26 21 1.00 (ref) 1.00 (ref)
       CT 41 41 1.24 (0.60–2.54) 1.27 (0.58–2.49) 0.6900
       CC 17 29 2.11 (0.92–4.84) 2.16 (0.97–4.38) 0.1169
   Alcohol drinking behaviors
    Non-drinkers
       TT 99 78 1.00 (ref) 1.00 (ref)
       CT 150 143 1.21 (0.83–1.76) 1.28 (0.85–2.04) 0.3672
       CC 62 97 1.99 (1.28–3.07) 2.04 (1.17–2.89) 0.0028 *
    Drinkers
       TT 18 11 1.00 (ref) 1.00 (ref)
       CT 24 20 1.36 (0.52–3.55) 1.29 (0.48–3.42) 0.6933
       CC 9 13 2.36 (0.76–7.34) 2.24 (0.74–6.93) 0.2239
   BMI
    <24
       TT 57 49 1.00 (ref) 1.00 (ref)
       CT 81 86 1.24 (0.76–2.01) 1.22 (0.73–1.98) 0.4686
       CC 37 58 1.82 (1.04–3.20) 1.84 (1.09–3.35) 0.0498 *
    ≥24
       TT 60 40 1.00 (ref) 1.00 (ref)
       CT 93 77 1.24 (0.75–2.05) 1.21 (0.72–2.34) 0.4712
       CC 34 52 2.29 (1.27–4.13) 2.38 (1.34–3.97) 0.0084 *

a, by univariate logistic regression analysis; b,c by multivariate logistic regression analysis after the adjustments of confounding factors; CI, confidence interval; aOR, adjusted odds ratio; *: p < 0.05; the significant parts are marked in bold.

2.5. Genotype-Phenotype Correlation of MiR196a-2 among Controls

We further intended to investigate the functional levels of mir196a-2 expression in serum, and correlate the phenotypic patterns with their corresponding mir196a-2 genotypes. For this purpose, we examined 34 serum samples from controls. Among these samples, 9 individuals had the TT genotype, 18 had the CT genotype, and 7 had the CC genotype at mir196a-2 rs11614913. We observed a significant difference in the mean expression level of serum mir196a-2 among the three genotypes (p < 0.0001) in ANOVA analysis. In particular, individuals carrying the homozygous variant genotype CC had significantly higher levels of serum mir196a-2 compared with those carrying the TT genotype (p < 0.0001) (Figure 2A). When combining the CT and CC genotypes, the expression of mir196a-2 remained higher compared to the TT genotype, although the difference did not reach a significant level from the viewpoint of statistics (p = 0.0656) (Figure 2B).

Figure 2.

Figure 2

Correlation between mir196a-2 genotypes and mir196a-2 expression in the serum of healthy subjects. (A) comparing three different genotypes; (B) comparing TT and CT + CC genotypes. * Statistically significant different from TT genotypes; # Statistically significant different from CT genotypes.

3. Discussion

In this study, we provided evidence that the mir196a-2 rs11614913 CC genotype and C allele may contribute to a higher risk of CRC (Table 2 and Table 4). The mir146a rs2910164 SNP was not associated with CRC risk in Taiwan (Table 3). Our findings are consistent with a previous study by Zhan, which reported an association between the mir196a-2 rs11614913 C allele and increased CRC risk in China, [43]. However, two studies have reported conflicting results, suggesting that individuals carrying the mir196a-2 rs11614913 TT genotypic pattern are at higher risk of developing CRC than those carrying the CC genotypic pattern in Iran and China [42,45]. The inconsistency between the findings of Zhan and Lv, despite studying similar populations, cannot be attributed to ethnic heterogeneity but rather may be influenced by sampling bias or other factors. It is worth noting that the CC genotype frequency in Lv’s study is unusually low. For Europeans, it appears that mir196a-2 rs11614913 is not associated with CRC susceptibility [28,29,38,40]. For Japanese, the genotype of mir196a-2 rs11614913 is not associated with CRC susceptibility either [31]. Thus far, the studies that have reported a positive association between mir196a-2 rs11614913 and CRC risk have focused on Asian populations ([43] and the current study). The conflicting results observed in Iranian [45,48] and Chinese [42,43,47] populations may be resolved through further investigations involving larger sample sizes. It should be emphasized that the frequency of the T allele of mir196a-2 rs11614913 varies significantly across different ethnicities, ranging from 18.8% in Africans, 39.4% in Europeans, 41.1% in Mexicans, 30.7% in South Asians, and 54.8% in East Asians (Supplemental Table S2). The T allele frequency in our controls (56.4%) is similar to that in East Asians (54.8%). The T allele represents the major allele in East Asians but is the minor allele in all other ethnicities. Conducting additional studies on different populations could provide insights and help reconcile the discrepancies. All the literature investigating the associations between mir196a-2 rs11614913 genotypes and CRC risk was summarized in Table 6, including the current study.

Table 6.

Literature reports of the associations between mir196a-2 rs11614913 genotypes and CRC risk.

First Author Year Ethnicity TT, CT, CC Genotype # of the Controls TT, CT, CC Genotype # of the Cases OR (95%CI) a p-Value b Ref #
Chen 2011 Chinese 107:206:94 35:64:27 0.94 (0.71–1.25) 0.715 [47]
Zhan 2011 Chinese 163:267:113 56:128:68 1.32 (1.07–1.64) 0.011 [43]
Min 2012 Korean 148:254:100 125:201:120 1.19 (0.99–1.42) 0.073 [37]
Hezova 2012 European 22:103:87 26:89:82 0.95 (0.71–1.27) 0.811 [28]
Vinci 2013 European 11:84:83 12:86:62 0.81 (0.59–1.12) 0.231 [29]
Lv 2013 Chinese 91:331:109 114:223:10 0.50 (0.41–0.61) <0.001 [42]
Kupcinskas 2014 European 54:174:199 27:87:79 0.86 (0.67–1.10) 0.254 [40]
Parlayan 2014 Japanese 390:679:282 34:59:23 0.97 (0.74–1.27) 0.881 [31]
Dikaiakos 2015 European 117:149:33 69:69:19 0.92 (0.69–1.23) 0.624 [38]
Chayeb 2018 Tunisian 29:85:47 31:82:39 0.89 (0.65–1.22) 0.508 [30]
Haerian 2018 Iranian 187:551:505 262:196:449 0.90 (0.80–1.02) 0.105 [45]
Soltanian 2021 Iranian 56:122:108 29:91:74 1.11 (0.85–1.45) 0.477 [48]
Yueh 2023 Taiwanese 117:174:71 89:163:110 1.45 (1.18–1.78) 0.001 current

OR: Odds ratio; CI: confidence interval; Ref #: Reference number; a C allele versus T allele at mir196a-2 rs11614913; b p-Values were calculated by Chi-square with Yates’ correction.

Quantification of mir196a-2 expression levels in serum can offer functional evidence that supports the role of mir196a-2 in the etiology of CRC. However, previous studies often lack the necessary data in this regard. Circulating miRNAs are believed to be encapsulated in exosomes, which protect them from degradation by RNase enzymes. Therefore, the expression of mir196a-2 could potentially serve as a measurable biomarker for CRC. In our study, we observed significantly higher expression levels of mir196a-2 carrying the homozygous variant genotype (CC) of mir196a-2 rs11614913 compared to those carrying the wild-type TT genotype. This finding provides biological plausibility for the association of CC genotypes with increased CRC risk. The observed difference in RNA expression levels aligns with the genotypic data, supporting that the CC genotype has a significant effect on CRC risk. These findings are consistent with a previous report by Zhan, which reported higher expression levels of mir196a-2 in tumor tissue of patients carrying the CT and CC genotypes compared to those with the TT genotype [43].

The genotypes of mir196a-2 rs11614913 may have a significant impact on various unresolved aspects of CRC. For example, several studies have examined the potential prognostic value of rs11614913 in Asian CRC patients. In 2018, Pao and colleagues showed that CRC patients carrying the rs11614913 CC genotype had a shorter overall survival time among 188 Taiwanese CRC cases [49]. Similarly, in 2011, Jang and colleagues reported that the heterozygous TC genotype, not the homozygous one, may serve as a risk factor for unfavorable overall survival in 446 Korean CRC patients [50]. Further investigations are necessary to validate these findings, as they were conducted exclusively in Asian populations. However, these findings hold potential clinical significance and emphasize the importance of exploring the prognostic value of mir196a-2 rs11614913 in other populations as well.

This study has several limitations that should be acknowledged. Firstly, the absence of CRC tissues prevented us from comparing mir196a-2 expression levels between CRC tissues and adjacent normal tissues. However, the measurements of serum mir196a-2 expression in controls provided an important genotype–phenotype (gene expression) correlation, supporting the observed association between genotypes and CRC risk. Secondly, the CRC patients included in our study were heterogeneous in terms of clinical features and treatments, and some patients were lost to follow-up, which hindered the analyses on the association between the mir196a-2 SNP and CRC prognosis. Thirdly, this investigation was conducted within a single medical center, China Medical University Hospital (CMUH). Although we have extinguished the possibility of population heterogeneity, further multi-center studies with larger sample sizes in the future are important to validate the current findings. Finally, given the small sample size, we only studied two SNPs. Future studies should include a more comprehensive, genome-wide analysis of SNPs in a significantly larger number of subjects.

In conclusion, the findings of the current study demonstrate that the C allele and CC genotype of mir196a-2 rs11614913 are closely correlated to the increased CRC risk among the Taiwanese. Moreover, the CC genotype is correlated with significantly higher levels of serum mir196a-2 expression. Therefore, in conjunction with mir196a-2 rs11614913 genotyping, the elevated serum levels of mir196a-2 may serve as a novel circulating marker for the early detection of CRC.

4. Materials and Methods

4.1. Study Population

The recruitment of CRC cases and healthy controls followed the same protocols as the routine sample collection work conducted in the Terry Fox Lab, as described in our previous papers [13,14]. Briefly, the CRC cases were recruited from CMUH from 2002 to 2008, and comprehensive pathological data, including staging, were accurately recorded. Controls were matched 1:1 to cases by age (with a difference ≤5 years) and gender. The age ranges for the patient and control groups were 42–89 and 44–90, respectively. The smokers include current and former smokers. Former smokers are those who have smoked at least 100 cigarettes in their lifetime but who have quit smoking for at least one year at the time of the interview. The drinkers include current and former drinkers. A current drinker is a person who consumed alcohol at least weekly in the year before the interview. Former drinkers are those who had quit drinking at least one year ago at the time of the interview. For each study participant, 10 mL of blood were collected and then delivered to the laboratory for DNA extraction and serum isolation within 24 h. The isolated DNA and serum were long-term stored at −80 °C and ready to use in this study. The study was approved by the Institutional Review Board of CMUH (coding number: DMR99-IRB-108). The staging status of the CRC patients was defined as Stage 1 to 4 for T1-2 N0 M0, T3-4 N0 M0, Tcarcinoma in situ-4 N1-2 M0, and Tcarcinoma in situ-4 N0-2 M1, respectively, according to the AJCC/UICC colorectal cancer staging classification standard.

4.2. Genotyping Methodology of Mir146a and Mir196a-2 Polymorphisms

Genomic DNA was extracted from the peripheral blood samples of each subject using a Qiagen kit (Qiagen, Chatsworth, CA, USA), according to the procedures described in our previous publication [51,52]. The genotyping of mir146a and mir196a-2 polymorphic sites was conducted using the typical polymerase chain reaction restriction fragment length polymorphism (PCR-RFLP) method. For the mir146a rs2910164 polymorphism, the sequences of forward and reverse primers were 5′-CATGGGTTGTGTCAGTGTCAGAGCT-3′ and 5′-TGCCTTCTGTCTCCAGTCTTCCAA-3′, respectively. For the mir196a-2 rs11614913 polymorphism, the sequences of forward and reverse primers are 5′-CCCCTTCCCTTCTCCTCCAGATA-3′ and 5′-CGAAAACCGACTGATGTAACTCCG-3′, respectively. PCR amplification was carried out using a PCR Thermocycler (Bio-RAD, Hercules, CA, USA) under the following conditions: initial denaturation at 94 °C for 5 min, followed by denaturation at 94 °C for 30 s, annealing at 64 °C for 40 s, and extension at 72 °C for 45 s. After 35 cycles of PCR, a final extension step was carried out at 72 °C for 10 min. The PCR amplicons for mir146a and mir196a-2 were visualized after 3%-agarose gel 100-volt electrophoresis, and then digested with Sac I and Msp I restriction enzymes. The digestion products were subsequently verified through 4%-agarose gel 100-volt electrophoresis. The results of mir146a rs2910164 enzyme digestion presented three distinctive patterns: an unaltered single 147 bp fragment representing the GG genotype, fully digested fragments of 122 and 25 bp indicating the CC genotype, and fragments of 147, 122, and 25 bp representing the heterozygous GC genotype [53]. The results of mir196a-2 rs11614913 enzyme digestion exhibited another three different patterns: an intact single 149 bp fragment representing the TT genotype, fully-digested fragments of 125 and 24 bp representing the homozygous variant CC genotype, and fragments of 149, 125, and 24 bp representing the heterozygous variant CT genotype [54].

4.3. Quantitative Reverse Transcription Polymerase Chain Reaction for Examining Mir196a-2 Transcriptional Expression

miRNA was extracted from serum using the miRNeasy Mini Isolation kit (Qiagen, Redwood, CA, USA) in accordance with the manufacturer’s instructions. Then, 1 μg of these miRNA samples were subsequently employed as templates for complementary DNA (cDNA) synthesis, utilizing the miScript II RT kit (Qiagen, Redwood, CA, USA). Then the reverse transcription (RT) reaction was conducted with the system set at: 42 °C for 15 min, 85 °C for 5 s, and then held at 4 °C. After the RT reaction was finished, the cDNA adducts were diluted at a 1:100 ratio, and 1 μL of the diluted cDNA adducts was subjected to the subsequent quantitative RT-PCR. For the quantification of mir196a-2 expression, the miScript SYBR Green PCR kit (Qiagen, Redwood City, CA, USA) was employed. All primers utilized were part of the SYBR green assays for mir196a-2 (Qiagen, Redwood City, CA, USA). The small nuclear RNA U6 was used as an internal control.

4.4. Statistical Analysis

The distributions of categorized age, gender, personal habits, different genotypes, and alleles among the subgroups were compared using Pearson’s chi-square test. The associations between different genotypes and CRC risk were assessed using individual odds ratios (ORs) with corresponding 95% confidence intervals (CIs). The serum mir196a-2 expression levels between different genotypes were compared with the unpaired Student’s t-test (for two groups, Figure 2B) and analysis of variance (ANOVA) (for three groups, Figure 2A). Statistical significance was defined as a p-Value less than 0.05.

Acknowledgments

The authors would like to express their gratitude to the Tissue-Bank of China Medical University Hospital for their exceptional technical assistance. The authors also extend their appreciation to all the study participants, doctors, nurses, and colleagues involved in the study. Special thanks are given to Yu-Chen Hsiau, Yu-Hsin Lin, and Tai-Lin Huang for their excellent techniques and dedicated efforts.

Supplementary Materials

The supporting information can be downloaded at: https://www.mdpi.com/article/10.3390/ijms241411613/s1.

Author Contributions

Conceptualization, T.-C.Y., D.-T.B., C.-W.T. and W.-S.C. Collection, J.-S.P., Y.-C.H. and D.-T.B. Data curation, M.-C.M., J.-S.P. and C.-W.T. Genotyping, Y.-C.W., Y.-T.C. and W.-S.C. Statistics, Y.-C.Y. and C.-W.T. Phenotyping, D.-T.B., J.G. and W.-S.C. Project administration, T.-C.Y. and D.-T.B. Supervision, D.-T.B. and C.-W.T. Validation, T.-C.Y. and W.-S.C. Writing—original draft, T.-C.Y. and C.-W.T. Writing—review and editing, D.-T.B. and J.G. All authors have read and agreed to the published version of the manuscript.

Institutional Review Board Statement

The study was conducted in accordance with the Declaration of Helsinki and approved by the Institutional Review Board of China Medical University Hospital (DMR99-IRB-108).

Informed Consent Statement

Informed consent was obtained from all subjects involved in the study.

Data Availability Statement

The genotyping results and clinical data supporting the findings of this study are available from the corresponding authors upon reasonable requests via email at artbau2@gmail.com.

Conflicts of Interest

The authors declare no conflict of interest.

Funding Statement

This study received significant support from Taichung Armed Forces General Hospital (TCAFGH-D-111021) and China Medical University and Asia University (CMU111-ASIA-02). The funders had no involvement in the study design, data collection, statistical analysis, decision to publish, or manuscript preparation.

Footnotes

Disclaimer/Publisher’s Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.

References

  • 1.Siegel R.L., Wagle N.S., Cercek A., Smith R.A., Jemal A. Colorectal cancer statistics, 2023. CA Cancer J. Clin. 2023;73:233–254. doi: 10.3322/caac.21772. [DOI] [PubMed] [Google Scholar]
  • 2.Sung H., Ferlay J., Siegel R.L., Laversanne M., Soerjomataram I., Jemal A., Bray F. Global Cancer Statistics 2020: GLOBOCAN Estimates of Incidence and Mortality Worldwide for 36 Cancers in 185 Countries. CA Cancer J. Clin. 2021;71:209–249. doi: 10.3322/caac.21660. [DOI] [PubMed] [Google Scholar]
  • 3.You L., Lv Z., Li C., Ye W., Zhou Y., Jin J., Han Q. Worldwide cancer statistics of adolescents and young adults in 2019: A systematic analysis of the Global Burden of Disease Study 2019. ESMO Open. 2021;6:100255. doi: 10.1016/j.esmoop.2021.100255. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 4.Dong W., Kim U., Rose J., Hoehn R.S., Kucmanic M., Eom K., Li S., Berger N.A., Koroukian S.M. Geographic Variation and Risk Factor Association of Early Versus Late Onset Colorectal Cancer. Cancers. 2023;15:1006. doi: 10.3390/cancers15041006. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 5.Agache A., Mustatea P., Mihalache O., Bobirca F.T., Georgescu D.E., Jauca C.M., Birligea A., Doran H., Patrascu T. Diabetes Mellitus as a Risk-factor for Colorectal Cancer Literature Review—Current Situation and Future Perspectives. Chirurgia. 2018;113:603–610. doi: 10.21614/chirurgia.113.5.603. [DOI] [PubMed] [Google Scholar]
  • 6.Li N., Lu B., Luo C., Cai J., Lu M., Zhang Y., Chen H., Dai M. Incidence, mortality, survival, risk factor and screening of colorectal cancer: A comparison among China, Europe, and northern America. Cancer Lett. 2021;522:255–268. doi: 10.1016/j.canlet.2021.09.034. [DOI] [PubMed] [Google Scholar]
  • 7.Kao P.S., Lin J.K., Wang H.S., Yang S.H., Jiang J.K., Chen W.S., Lin T.C., Li A.F., Liang W.Y., Chang S.C. The impact of family history on the outcome of patients with colorectal cancer in a veterans’ hospital. Int. J. Colorectal Dis. 2009;24:1249–1254. doi: 10.1007/s00384-009-0774-3. [DOI] [PubMed] [Google Scholar]
  • 8.Yeh Y.L., Li M., Kwok O.M., Ma P., Chen L.S. Chinese Americans’ Family History of Colorectal Cancer Communication with Primary Care Physicians. Health Educ. Behav. 2022;49:169–178. doi: 10.1177/10901981211009750. [DOI] [PubMed] [Google Scholar]
  • 9.Hung Y.C., Chang W.S., Chou A.K., Pei J.S., Yang M.D., Yang H.R., Yang T.M., Wang Y.C., Hsiau Y.C., Chen C.P., et al. Association of Adiponectin Genotypes with Colorectal Cancer Susceptibility in Taiwan. Anticancer Res. 2020;40:1297–1306. doi: 10.21873/anticanres.14071. [DOI] [PubMed] [Google Scholar]
  • 10.Wu M.H., Chen C.H., Chen C.P., Huang T.L., Yueh T.C., Wang Z.H., Tsai C.W., Pei J.S., Mong M.C., Yang Y.C., et al. Contribution of 5-Methyltetrahydrofolate-Homocysteine Methyltransferase Reductase Genotypes to Colorectal Cancer in Taiwan. Anticancer Res. 2022;42:2375–2382. doi: 10.21873/anticanres.15716. [DOI] [PubMed] [Google Scholar]
  • 11.Wu M.H., Hung Y.W., Gong C.L., Chao C.C., Yueh T.C., Wang S.C., Lai Y.L., Hsu S.W., Fu C.K., Wang Y.C., et al. Contribution of Caspase-8 Genotypes to Colorectal Cancer Risk in Taiwan. Anticancer Res. 2019;39:2791–2797. doi: 10.21873/anticanres.13406. [DOI] [PubMed] [Google Scholar]
  • 12.Wu M.H., Tzeng H.E., Wu C.N., Yueh T.C., Peng Y.C., Tsai C.H., Wang Y.C., Ke T.W., Pei J.S., Chang W.S., et al. Association of Matrix Metalloproteinase-9 rs3918242 Promoter Genotypes with Colorectal Cancer Risk. Anticancer Res. 2019;39:6523–6529. doi: 10.21873/anticanres.13867. [DOI] [PubMed] [Google Scholar]
  • 13.Wu M.H., Yueh T.C., Chang W.S., Tsai C.W., Fu C.K., Yang M.D., Yu C.C., Bau D.T. Contribution of Matrix Metalloproteinase-1 Genotypes to Colorectal Cancer in Taiwan. Cancer Genom. Proteom. 2021;18:245–251. doi: 10.21873/cgp.20255. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 14.Yueh T.C., Hung Y.C., Lee H.T., Yang M.D., Wang Z.H., Yang Y.C., Ke T.W., Pei J.S., Tsai C.W., Bau D.T., et al. Role of Matrix Metallopeptidase-2 Genotypes in Taiwanese Patients with Colorectal Cancer. Anticancer Res. 2022;42:5335–5342. doi: 10.21873/anticanres.16040. [DOI] [PubMed] [Google Scholar]
  • 15.Devara D., Choudhary Y., Kumar S. Role of MicroRNA-502-3p in Human Diseases. Pharmaceuticals. 2023;16:532. doi: 10.3390/ph16040532. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 16.Kim W.R., Park E.G., Lee D.H., Lee Y.J., Bae W.H., Kim H.S. The Tumorigenic Role of Circular RNA-MicroRNA Axis in Cancer. Int. J. Mol. Sci. 2023;24:3050. doi: 10.3390/ijms24033050. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 17.Tajik F., Alian F., Yousefi M., Azadfallah A., Hoseini A., Mohammadi F., Karimi-Dehkordi M., Alizadeh-Fanalou S. MicroRNA-372 acts as a double-edged sword in human cancers. Heliyon. 2023;9:e15991. doi: 10.1016/j.heliyon.2023.e15991. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 18.Kontham S.S., Walter C.E.J., Shankaran Z.S., Ramanathan A., Karuppasamy N., Johnson T. A microRNA binding site polymorphism in the 3′ UTR region of VEGF-A gene modifies colorectal cancer risk based on ethnicity: A meta-analysis. J. Egypt Natl. Canc. Inst. 2022;34:18. doi: 10.1186/s43046-022-00118-3. [DOI] [PubMed] [Google Scholar]
  • 19.Wang Z., Zhu X., Zhai H., Wang Y., Hao G. Integrated analysis of mRNA-single nucleotide polymorphism-microRNA interaction network to identify biomarkers associated with prostate cancer. Front. Genet. 2022;13:922712. doi: 10.3389/fgene.2022.922712. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 20.Sharma G., Mo J.S., Lamichhane S., Chae S.C. MicroRNA 133A Regulates Cell Proliferation, Cell Migration, and Apoptosis in Colorectal Cancer by Suppressing CDH3 Expression. J. Cancer. 2023;14:881–894. doi: 10.7150/jca.82916. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 21.Candiello E., Reato G., Verginelli F., Gambardella G., Ambrosio D.A., Calandra N., Orzan F., Iuliano A., Albano R., Sassi F., et al. MicroRNA 483-3p overexpression unleashes invasive growth of metastatic colorectal cancer via NDRG1 downregulation and ensuing activation of the ERBB3/AKT axis. Mol. Oncol. 2023;17:1280–1301. doi: 10.1002/1878-0261.13408. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 22.Pathak S., Meng W.J., Sriramulu S., Jothimani G., Jangamreddy J.R., Banerjee A., Ganesan A.T., Adell G., Zhang X., Sun Zhang A., et al. Association of microRNA-652 expression with radiation response of colorectal cancer: A study from rectal cancer patients in a Swedish trial of preoperative radiotherapy. Curr. Gene Ther. 2023 doi: 10.2174/1566523223666230418111613. ahead of print . [DOI] [PubMed] [Google Scholar]
  • 23.Zhao D.Y., Yin T.F., Sun X.Z., Zhou Y.C., Wang Q.Q., Zhou G.Y., Yao S.K. microRNA-627-5p inhibits colorectal cancer cell proliferation, migration and invasion by targeting Wnt2. World J. Gastrointest. Oncol. 2023;15:318–331. doi: 10.4251/wjgo.v15.i2.318. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 24.Wang D., Wang Y., Lin Z., Cai L. Association between miRNA-146a polymorphism and lung cancer susceptibility: A meta-analysis involving 6506 cases and 6576 controls. Gene. 2020;757:144940. doi: 10.1016/j.gene.2020.144940. [DOI] [PubMed] [Google Scholar]
  • 25.Li X.Y., Huang Z.J., Li J.P., Gao X.R. rs3735664 Polymorphism Affecting ELFN1-AS1 Adsorption on miR-1231 is Associated with Colorectal Cancer Susceptibility and Tumor Stage. Biomed. Environ. Sci. 2023;36:381–383. doi: 10.3967/bes2023.045. [DOI] [PubMed] [Google Scholar]
  • 26.Jazdzewski K., Murray E.L., Franssila K., Jarzab B., Schoenberg D.R., de la Chapelle A. Common SNP in pre-miR-146a decreases mature miR expression and predisposes to papillary thyroid carcinoma. Proc. Natl. Acad. Sci. USA. 2008;105:7269–7274. doi: 10.1073/pnas.0802682105. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 27.Santos J.S.D., Zunta G.L., Negrini A.B., Ribeiro M.S.G., Martinez C.A.R., Ribeiro M.L., Lourenco G.J., Ortega M.M. The association of a single-nucleotide variant in the microRNA-146a with advanced colorectal cancer prognosis. Tumour Biol. 2020;42:1010428320923856. doi: 10.1177/1010428320923856. [DOI] [PubMed] [Google Scholar]
  • 28.Hezova R., Kovarikova A., Bienertova-Vasku J., Sachlova M., Redova M., Vasku A., Svoboda M., Radova L., Kiss I., Vyzula R., et al. Evaluation of SNPs in miR-196-a2, miR-27a and miR-146a as risk factors of colorectal cancer. World J. Gastroenterol. 2012;18:2827–2831. doi: 10.3748/wjg.v18.i22.2827. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 29.Vinci S., Gelmini S., Mancini I., Malentacchi F., Pazzagli M., Beltrami C., Pinzani P., Orlando C. Genetic and epigenetic factors in regulation of microRNA in colorectal cancers. Methods. 2013;59:138–146. doi: 10.1016/j.ymeth.2012.09.002. [DOI] [PubMed] [Google Scholar]
  • 30.Chayeb V., Mahjoub S., Zitouni H., Jrah-Harzallah H., Zouari K., Letaief R., Mahjoub T. Contribution of microRNA-149, microRNA-146a, and microRNA-196a2 SNPs in colorectal cancer risk and clinicopathological features in Tunisia. Gene. 2018;666:100–107. doi: 10.1016/j.gene.2018.04.084. [DOI] [PubMed] [Google Scholar]
  • 31.Parlayan C., Ikeda S., Sato N., Sawabe M., Muramatsu M., Arai T. Association analysis of single nucleotide polymorphisms in miR-146a and miR-196a2 on the prevalence of cancer in elderly Japanese: A case-control study. Asian Pac. J. Cancer Prev. 2014;15:2101–2107. doi: 10.7314/APJCP.2014.15.5.2101. [DOI] [PubMed] [Google Scholar]
  • 32.Ying H.Q., Peng H.X., He B.S., Pan Y.Q., Wang F., Sun H.L., Liu X., Chen J., Lin K., Wang S.K. MiR-608, pre-miR-124-1 and pre-miR26a-1 polymorphisms modify susceptibility and recurrence-free survival in surgically resected CRC individuals. Oncotarget. 2016;7:75865–75873. doi: 10.18632/oncotarget.12422. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 33.Lindor N.M., Larson M.C., DeRycke M.S., McDonnell S.K., Baheti S., Fogarty Z.C., Win A.K., Potter J.D., Buchanan D.D., Clendenning M., et al. Germline miRNA DNA variants and the risk of colorectal cancer by subtype. Genes Chromosomes Cancer. 2017;56:177–184. doi: 10.1002/gcc.22420. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 34.Jiang J., Zhang S., Tang W., Qiu Z. Lack of association between miR-146a rs2910164 C/G locus and colorectal cancer: From a case-control study to a meta-analysis. Biosci. Rep. 2021;41:BSR20191729. doi: 10.1042/BSR20191729. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 35.Mao Y., Li Y., Jing F., Cai S., Zhang Z., Li Q., Ma X., Wang J., Jin M., Chen K. Association of a genetic variant in microRNA-146a with risk of colorectal cancer: A population-based case-control study. Tumour Biol. 2014;35:6961–6967. doi: 10.1007/s13277-014-1916-y. [DOI] [PubMed] [Google Scholar]
  • 36.Gao X., Zhu Z., Zhang S. miR-146a rs2910164 polymorphism and the risk of colorectal cancer in Chinese population. J. Cancer Res. Ther. 2018;14:S97–S99. doi: 10.4103/0973-1482.165864. [DOI] [PubMed] [Google Scholar]
  • 37.Min K.T., Kim J.W., Jeon Y.J., Jang M.J., Chong S.Y., Oh D., Kim N.K. Association of the miR-146aC>G, 149C>T, 196a2C>T, and 499A>G polymorphisms with colorectal cancer in the Korean population. Mol. Carcinog. 2012;51((Suppl. S1)):E65–E73. doi: 10.1002/mc.21849. [DOI] [PubMed] [Google Scholar]
  • 38.Dikaiakos P., Gazouli M., Rizos S., Zografos G., Theodoropoulos G.E. Evaluation of genetic variants in miRNAs in patients with colorectal cancer. Cancer Biomark. 2015;15:157–162. doi: 10.3233/CBM-140449. [DOI] [PubMed] [Google Scholar]
  • 39.Chae Y.S., Kim J.G., Lee S.J., Kang B.W., Lee Y.J., Park J.Y., Jeon H.S., Park J.S., Choi G.S. A miR-146a polymorphism (rs2910164) predicts risk of and survival from colorectal cancer. Anticancer Res. 2013;33:3233–3239. [PubMed] [Google Scholar]
  • 40.Kupcinskas J., Bruzaite I., Juzenas S., Gyvyte U., Jonaitis L., Kiudelis G., Skieceviciene J., Leja M., Pauzas H., Tamelis A., et al. Lack of association between miR-27a, miR-146a, miR-196a-2, miR-492 and miR-608 gene polymorphisms and colorectal cancer. Sci. Rep. 2014;4:5993. doi: 10.1038/srep05993. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 41.Ma L., Zhu L., Gu D., Chu H., Tong N., Chen J., Zhang Z., Wang M. A genetic variant in miR-146a modifies colorectal cancer susceptibility in a Chinese population. Arch. Toxicol. 2013;87:825–833. doi: 10.1007/s00204-012-1004-2. [DOI] [PubMed] [Google Scholar]
  • 42.Lv M., Dong W., Li L., Zhang L., Su X., Wang L., Gao L., Zhang L. Association between genetic variants in pre-miRNA and colorectal cancer risk in a Chinese population. J. Cancer Res. Clin. Oncol. 2013;139:1405–1410. doi: 10.1007/s00432-013-1456-7. [DOI] [PubMed] [Google Scholar]
  • 43.Zhan J.F., Chen L.H., Chen Z.X., Yuan Y.W., Xie G.Z., Sun A.M., Liu Y. A functional variant in microRNA-196a2 is associated with susceptibility of colorectal cancer in a Chinese population. Arch. Med. Res. 2011;42:144–148. doi: 10.1016/j.arcmed.2011.04.001. [DOI] [PubMed] [Google Scholar]
  • 44.Zhu L., Chu H., Gu D., Ma L., Shi D., Zhong D., Tong N., Zhang Z., Wang M. A functional polymorphism in miRNA-196a2 is associated with colorectal cancer risk in a Chinese population. DNA Cell Biol. 2012;31:350–354. doi: 10.1089/dna.2011.1348. [DOI] [PubMed] [Google Scholar]
  • 45.Haerian M.S., Haerian B.S., Molanaei S., Kosari F., Sabeti S., Bidari-Zerehpoosh F., Abdolali E. MIR196A2 rs11614913 contributes to susceptibility to colorectal cancer in Iranian population: A multi-center case-control study and meta-analysis. Gene. 2018;669:82–90. doi: 10.1016/j.gene.2018.05.082. [DOI] [PubMed] [Google Scholar]
  • 46.Toraih E.A., Fawzy M.S., Mohammed E.A., Hussein M.H., El-Labban M.M. MicroRNA-196a2 Biomarker and Targetome Network Analysis in Solid Tumors. Mol. Diagn. Ther. 2016;20:559–577. doi: 10.1007/s40291-016-0223-2. [DOI] [PubMed] [Google Scholar]
  • 47.Chen H., Sun L.Y., Chen L.L., Zheng H.Q., Zhang Q.F. A variant in microRNA-196a2 is not associated with susceptibility to and progression of colorectal cancer in Chinese. Intern. Med. J. 2012;42:e115–e119. doi: 10.1111/j.1445-5994.2011.02434.x. [DOI] [PubMed] [Google Scholar]
  • 48.Soltanian A.R., Hosseini B., Mahjub H., Bahreini F., Nazemalhosseini Mojarad E., Ghaffari M.E. Association between rs11614913 Polymorphism of The MiR-196-a2 Gene and Colorectal Cancer in The Presence of Departure from Hardy-Weinberg Equilibrium. Cell J. 2021;23:313–318. doi: 10.22074/cellj.2021.7295. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 49.Pao J.B., Lu T.L., Ting W.C., Chen L.M., Bao B.Y. Association of Genetic Variants of Small Non-Coding RNAs with Survival in Colorectal Cancer. Int. J. Med. Sci. 2018;15:217–222. doi: 10.7150/ijms.22402. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 50.Jang M.J., Kim J.W., Min K.T., Jeon Y.J., Oh D., Kim N.K. Prognostic significance of microRNA gene polymorphisms in patients with surgically resected colorectal cancer. Exp. Ther. Med. 2011;2:1127–1132. doi: 10.3892/etm.2011.321. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 51.Yang M.D., Lin K.C., Lu M.C., Jeng L.B., Hsiao C.L., Yueh T.C., Fu C.K., Li H.T., Yen S.T., Lin C.W., et al. Contribution of matrix metalloproteinases-1 genotypes to gastric cancer susceptibility in Taiwan. Biomedicine. 2017;7:10. doi: 10.1051/bmdcn/2017070203. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 52.Tsai C.W., Chang W.S., Xu Y., Huang M., Bau D.T., Gu J. Associations of genetically predicted circulating insulin-like growth factor-1 and insulin-like growth factor binding protein-3 with bladder cancer risk. Mol. Carcinog. 2021;60:726–733. doi: 10.1002/mc.23334. [DOI] [PubMed] [Google Scholar]
  • 53.Pei J.S., Chang W.S., Hsu P.C., Chen C.C., Chin Y.T., Huang T.L., Hsu Y.N., Kuo C.C., Wang Y.C., Tsai C.W., et al. Significant Association Between the MiR146a Genotypes and Susceptibility to Childhood Acute Lymphoblastic Leukemia in Taiwan. Cancer Genom. Proteom. 2020;17:175–180. doi: 10.21873/cgp.20178. [DOI] [PMC free article] [PubMed] [Google Scholar]
  • 54.Chen C.C., Hsu P.C., Shih L.C., Hsu Y.N., Kuo C.C., Chao C.Y., Chang W.S., Tsai C.W., Bau D.T., Pei J.S. MiR-196a-2 Genotypes Determine the Susceptibility and Early Onset of Childhood Acute Lymphoblastic Leukemia. Anticancer Res. 2020;40:4465–4469. doi: 10.21873/anticanres.14451. [DOI] [PubMed] [Google Scholar]

Associated Data

This section collects any data citations, data availability statements, or supplementary materials included in this article.

Supplementary Materials

Data Availability Statement

The genotyping results and clinical data supporting the findings of this study are available from the corresponding authors upon reasonable requests via email at artbau2@gmail.com.


Articles from International Journal of Molecular Sciences are provided here courtesy of Multidisciplinary Digital Publishing Institute (MDPI)

RESOURCES